12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC
Can-Fite Biopharma Announced It Published An Article In The Experimental And Therapeutic Medicine Journal, "Long-term Complete Response To Namodenoson In Liver Cancer With Child-Pugh B Cirrhosis
The Patient Participated In The Phase Ii Liver Cancer Study And Has Been Treated With Namodenoson For >7 Years Under Compassionate Use Program
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline
Can-Fite: Submits FDA With an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite BioPharma Ltd.
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
Can-Fite BioPharma Reports Reduced Losses in 2023
Can Fite Biofarma: Q4 Earnings Insights
Can Fite Biofarma (AMEX:CANF) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCan Fite Biofarma beat estimate
Can Fite Biofarma FY GAAP EPS $(0.01), Same YoY, Sales $743.00K Down From $810.00K YoY
Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $743.00 thousand in sales this quarter. This is a
Can-Fite Biopharma GAAP EPS of -$0.01, Revenue of $0.74M
Namodenoson Treatment for Pancreatic and Liver Cancer: Data Will Be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today announced its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic and liver cancer programs during numerous partnering meetings at the BIO-Europe Spring 2024 in Barcelona, Spain, on Mar 18-27, 2024
Can-Fite BioPharma Announced Notice Of Allowance In Canada For Its Patent Application Regarding Se Of Namodenoson For The Reduction Of Liver Fat In Patients With NASH
Can-Fite BioPharma Announced Notice Of Allowance In Canada For Its Patent Application Regarding Se Of Namodenoson For The Reduction Of Liver Fat In Patients With NASH
Buy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical Prospects
Can-Fite Shares Rise After Expansion of Licensing Deal
By Rob Curran Can-Fite BioPharma shares rose after the Israeli biotech concern expanded a licensing deal with Swiss firm drug-distribution firm Ewopharma to cover more indications. The deal expands
Can-Fite Expands the Out-Licensing Deal With Ewopharma to Include the Pancreatic Cancer Indication
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced th
Can-Fite: Top Scientific Journal Published Positive Data From the COMFORT-1 Phase III Psoriasis Study
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis. Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology
Can-Fite's Latest Innovation: Namodenoson Shows Significant Results in Obesity Reduction
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported ne
Can-Fite Receives Positive Response From FDA On Pediatric Study Plan For Treatment Of Children Suffering From Psoriasis With Piclidenoson
The plan has been submitted to allow enrollment of children with psoriasis to Can-Fite's upcoming Phase 3 pivotal clinical psoriasis studies, aiming at registration of Piclidenoson with both the FDA a
Can-Fite Biopharma Has Completed The Design Of Phase 2A Study Protocol For Pancreatic Cancer And Plans To Submit The Protocol Shortly To Ethical Committees For Approval, Study Will Aim To Enroll About 20 Patients To Establish Safety And Clinical Activity
Can-Fite Biopharma Has Completed The Design Of Phase 2A Study Protocol For Pancreatic Cancer And Plans To Submit The Protocol Shortly To Ethical Committees For Approval, Study Will Aim To Enroll About
Recap: Can Fite Biofarma Q3 Earnings
Can Fite Biofarma (AMEX:CANF) reported its Q3 earnings results on Thursday, November 30, 2023 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCan Fite Biofarma missed est
No Data